Sirolimus

Sirolimus is an mTOR inhibitor immunosuppressant used primarily to prevent kidney transplant rejection, treat lymphangioleiomyomatosis, and in topical form for facial angiofibromas.

Brief glance

The primary outcome is Longevity, but it's also used for Anti-Aging, Immune Support. This compound is considered a Small Molecule. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

Sirolimus is an immunosuppressant medication used with other drugs to prevent kidney transplant rejection by weakening the immune response that attacks the donor organ. It is also approved to treat lymphangioleiomyomatosis (LAM), a rare lung disease primarily affecting women of childbearing age. Known by the brand name Rapamune, it carries serious risks including kidney problems and increased infection susceptibility, so benefits and risks must be discussed with a doctor.

Sirolimus, also known as rapamycin, is a macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus and functions primarily as an mTOR inhibitor immunosuppressant. It prevents organ transplant rejection, particularly in renal transplants, by binding to FKBP12 to inhibit the mammalian target of rapamycin (mTOR), thereby suppressing T-cell activation, proliferation, and cytokine-driven responses. The drug also treats lymphangioleiomyomatosis (LAM), a rare lung disease, and perivascular epithelioid cell tumors (PEComa), with formulations like Rapamune, Fyarro, and Hyftor approved for these indications. Initially discovered for its antifungal properties, sirolimus was approved by the FDA in 1999 and is metabolized mainly by CYP3A4 in the liver and intestines.

Benefits

Sirolimus, an mTOR inhibitor, prevents renal transplant rejection by arresting the cell cycle of T- and B-lymphocytes, reducing acute rejection rates to 14-19% at 2-5 mg/day doses when combined with cyclosporine and steroids.¹,²,³ It exhibits synergistic efficacy with calcineurin inhibitors, enabling their dose reduction or elimination to mitigate nephrotoxicity while prolonging graft survival, as shown in animal models and low-to-moderate risk human trials.¹,² Additionally, sirolimus treats lymphangioleiomyomatosis by suppressing abnormal cell proliferation in affected lungs.³ Its lack of intrinsic nephrotoxicity supports long-term use in transplantation, potentially retarding chronic allograft vasculopathy.¹,²

Side effects

Sirolimus (Rapamune) is an immunosuppressant medication prescribed primarily to prevent organ rejection in kidney transplant recipients and to treat lymphangioleiomyomatosis, a rare lung disease.⁴ Common side effects include canker sores, headaches, constipation or diarrhea, swelling of the arms or legs, elevated blood pressure, and high cholesterol or triglycerides.⁴,⁵,⁶ More serious safety concerns include decreased platelet and white blood cell counts, kidney damage, serious infections, poor wound healing, and in rare cases, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).⁵,⁷,⁸ Additional adverse effects may include anemia, elevated liver enzymes, pneumonia, abnormal vision, acne, joint pain, and various neurological symptoms such as numbness, tingling, or seizures.³,⁵,⁷ Patients should monitor for signs of infection, unusual bruising or bleeding, decreased urine output, and wounds that do not heal properly, as these warrant immediate medical attention.⁷,⁸ The risk of certain side effects may increase when sirolimus is combined with other post-transplant medications such as calcineurin inhibitors or corticosteroids.⁴,⁹

Mechanisms of action

Sirolimus binds to the intracellular protein FKBP12, forming a complex that inhibits the mammalian target of rapamycin (mTOR), a serine/threonine kinase regulating cell growth, proliferation, and survival.¹⁰,¹¹,¹² This inhibition specifically targets mTOR complex 1 (mTORC1), blocking downstream signaling pathways like PI3K/Akt that drive cytokine-stimulated T-lymphocyte activation and proliferation in response to antigens and interleukins such as IL-2, IL-4, and IL-15.¹⁰,¹¹,¹³ As a result, progression from the G1 to S phase of the cell cycle is halted, suppressing T-cell and B-cell responses, antibody production, and overall immune activation distinct from calcineurin inhibitors.¹⁰,¹²,¹⁴ This mechanism underpins its use as an immunosuppressant in organ transplantation and other proliferative conditions.¹¹,¹³